Oculis Aktie
21,41USD | 0,10USD | 0,47% |
WKN DE: A3D8QG / ISIN: CH1242303498
Personal
2021 | 2022 | 2023 | |
---|---|---|---|
Personal am Ende des Jahres | 2 | 28 | 36 |
Umsatz pro Mitarbeiter in Mio. EUR | 0,00 | 0,00 | 0,00 |
Bilanz (in Mio. USD) - Aktiva
2021 | 2022 | 2023 | |
---|---|---|---|
Summe Umlaufvermögen | 1 | 26 | 120 |
Summe Anlagevermögen | 128 | 14 | 16 |
Summe Aktiva | 128 | 40 | 136 |
Bilanz (in Mio. USD) - Passiva
2021 | 2022 | 2023 | |
---|---|---|---|
Summe Fremdkapital | 8 | 146 | 25 |
Summe Eigenkapital | 121 | -106 | 111 |
Summe Passiva | 128 | 40 | 136 |
Adresse
Bahnhofstrasse 7, 6300 Zug | |
Telefon | +41 (58) 810-01-82 |
Internet | http://oculis.com |
Management
Anthony Adam Rosenberg
Chairman |
Arshad M. Khanani
Director |
Bastian Dehmel
Chief Development Officer |
Christina Maria Ackermann
Independent Director |
Daniel S. Char
Chief Legal Officer |
Geraldine O'Keeffe
Independent Director |
Lionel Carnot
Independent Director |
Martijn Kleijwegt
Independent Director |
Páll Ragnar Jóhannesson
Chief Business Officer |
Ramin Tadayoni
Chief Scientific Officer |
Rebecca Weil
Chief Commercial Officer |
Riad Sherif
Chief Executive Officer & Director |
Robert K. Warner
Director |
Sharon Klier
Chief Development Officer |
Snehal Shah
President-Research & Development |
Sylvia Cheung
Chief Financial Officer |
Virginia R. Dean
Chief Human Resources Officer |